High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014

Interleukin-2 (IL-2) was historically one of the few treatments for adults with stage IV solid tumors that could produce complete responses (CRs) that were often durable for decades without further therapy. The majority of complete responders with metastatic renal cell carcinoma (mRCC) and metastati...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Immunother Cancer
Autors principals: Dutcher, Janice P, Schwartzentruber, Douglas J, Kaufman, Howard L, Agarwala, Sanjiv S, Tarhini, Ahmad A, Lowder, James N, Atkins, Michael B
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2014
Matèries:
Review
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6889624/
https://ncbi.nlm.nih.gov/pubmed/31546315
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-014-0026-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars